Tags

Type your tag names separated by a space and hit enter

[Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
Presse Med. 1984 Feb 25; 13(8):483-6.PM

Abstract

Twelve patients with malignant hypercalcemia were treated with amino-hydroxypropylidene-diphosphonate (APD), a potent inhibitor of osteoclast-mediated bone resorption. The mean serum calcium levels fell from 3,48 +/- 0,27 mmol/l before treatment to 2,66 +/- 0,31 after 10 days of oral APD (10 to 15 mg/kg/d) as the sole agent (p less than 0,001). The molar calcium/creatine ratio in the 24-h urine was significantly reduced from 2,11 +/- 0,73 to 0,70 +/- 0,52 after ten days of treatment (p less than 0,001). Serum phosphorus and urine hydroxyproline did not change significantly. Tolerance was good except for two patients with hiatal hernia who developed oesophagitis. Ours results confirm that oral APD is an effective and simple treatment of malignant hypercalcemia.

Authors

Tubiana-Hulin M
No affiliation info available
de Vernejoul MC
No affiliation info available
Brière M
No affiliation info available
Miravet L
No affiliation info available
Clavel B
No affiliation info available

MeSH

Administration, OralAdultAgedBone NeoplasmsBone ResorptionCalciumDiphosphonatesFemaleHumansHypercalcemiaMaleMiddle AgedOsteolysisPamidronate

Pub Type(s)

Journal Article

Language

fre

PubMed ID

6230630

Citation

Tubiana-Hulin, M, et al. "[Treatment of Hypercalcemia in Osteolytic Metastases With Oral Amino-hydroxypropylidene-diphosphonate]." Presse Medicale (Paris, France : 1983), vol. 13, no. 8, 1984, pp. 483-6.
Tubiana-Hulin M, de Vernejoul MC, Brière M, et al. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate]. Presse Med. 1984;13(8):483-6.
Tubiana-Hulin, M., de Vernejoul, M. C., Brière, M., Miravet, L., & Clavel, B. (1984). [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate]. Presse Medicale (Paris, France : 1983), 13(8), 483-6.
Tubiana-Hulin M, et al. [Treatment of Hypercalcemia in Osteolytic Metastases With Oral Amino-hydroxypropylidene-diphosphonate]. Presse Med. 1984 Feb 25;13(8):483-6. PubMed PMID: 6230630.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate]. AU - Tubiana-Hulin,M, AU - de Vernejoul,M C, AU - Brière,M, AU - Miravet,L, AU - Clavel,B, PY - 1984/2/25/pubmed PY - 1984/2/25/medline PY - 1984/2/25/entrez SP - 483 EP - 6 JF - Presse medicale (Paris, France : 1983) JO - Presse Med VL - 13 IS - 8 N2 - Twelve patients with malignant hypercalcemia were treated with amino-hydroxypropylidene-diphosphonate (APD), a potent inhibitor of osteoclast-mediated bone resorption. The mean serum calcium levels fell from 3,48 +/- 0,27 mmol/l before treatment to 2,66 +/- 0,31 after 10 days of oral APD (10 to 15 mg/kg/d) as the sole agent (p less than 0,001). The molar calcium/creatine ratio in the 24-h urine was significantly reduced from 2,11 +/- 0,73 to 0,70 +/- 0,52 after ten days of treatment (p less than 0,001). Serum phosphorus and urine hydroxyproline did not change significantly. Tolerance was good except for two patients with hiatal hernia who developed oesophagitis. Ours results confirm that oral APD is an effective and simple treatment of malignant hypercalcemia. SN - 0755-4982 UR - https://www.unboundmedicine.com/medline/citation/6230630/[Treatment_of_hypercalcemia_in_osteolytic_metastases_with_oral_amino_hydroxypropylidene_diphosphonate]_ L2 - https://medlineplus.gov/bonecancer.html DB - PRIME DP - Unbound Medicine ER -